Nuveen LLC Buys New Position in TransMedics Group, Inc. $TMDX

Key Points

• Nuveen LLC acquired a new stake in TransMedics Group, Inc. by purchasing 88,096 shares valued at approximately $5.9 million, representing about 0.26% ownership in the company.
• TransMedics reported a strong quarterly performance with $0.92 EPS, exceeding expectations, and a revenue increase of 37.7% year-over-year, totaling $157.37 million.
• Analysts are optimistic about TransMedics, with several rating upgrades; the consensus target price has increased to $123.00, suggesting potential for growth in the stock.

Nuveen LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 88,096 shares of the company's stock, valued at approximately $5,927,000. Nuveen LLC owned about 0.26% of TransMedics Group as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of TransMedics Group by 104.7% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,309 shares of the company's stock valued at $3,183,000 after acquiring an additional 24,200 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in TransMedics Group by 2.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 304,367 shares of the company's stock worth $20,478,000 after buying an additional 6,934 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in TransMedics Group by 13.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company's stock worth $154,000 after buying an additional 278 shares during the last quarter. XTX Topco Ltd acquired a new stake in TransMedics Group in the 1st quarter worth about $1,301,000. Finally, HB Wealth Management LLC boosted its stake in TransMedics Group by 30.4% in the 1st quarter. HB Wealth Management LLC now owns 10,627 shares of the company's stock worth $715,000 after buying an additional 2,478 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Morgan Stanley raised their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. Oppenheimer raised their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Wall Street Zen lowered TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Canaccord Genuity Group raised their price target on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Trading Down 1.5%

Shares of NASDAQ TMDX traded down $1.76 during midday trading on Friday, hitting $114.96. The stock had a trading volume of 665,581 shares, compared to its average volume of 942,848. The company has a market capitalization of $3.92 billion, a price-to-earnings ratio of 59.57 and a beta of 2.18. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $172.78. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The company has a fifty day moving average price of $120.24 and a 200 day moving average price of $103.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company's revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 7.00% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.